ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profileMeiji Seika Pharma submitted ARCT-154 New Drug Application in JapanNew ARCT-154 booster clinical data demonstrate one-year durability across a panel of variantsReceived FDA Fast Track De.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Call Transcript August 7, 2023 Operator: Greetings, and welcome to Arcturus Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It […]